ISELIN, NJ -- Echo Therapeutics, Inc. has achieved a wireless mobile communication milestone, making it now possible for its continuous glucose sensor to transmit data to any mobile platform. This achievement marks the first key step in the strategic transformation of the Company's technology from a hospital-based medical system to a consumer product in both the wearable-health and diabetes segments.
Echo's Research & Development team created a new architecture to communicate wirelessly to mobile devices, including smartphones, using Bluetooth Low Energy (BLE) connectivity, keeping power consumption and cost to a minimum. Echo also developed a mobile application to demonstrate the transmitted glucose information on a smartphone. This new system leverages the progress made recently in both the skin preparation and glucose sensing technology and is currently being evaluated using in-house clinical feasibility studies. The Company received Institutional Review Board (IRB) approval for the clinical trial protocol and has commenced testing of these advancements.
"This milestone, announced in our recent webcast, is an important and critical first step forward for Echo as the application of our continuous glucose monitoring technology transitions to a consumer product. Importantly, the smartphone connectivity and mobile application now provides the ability to demonstrate our technology to potential partners," said Scott W. Hollander, Echo's President and CEO. "We look forward to updating shareholders with future advancements in the achievement of our goal of combining an advanced glucose sensor system with wireless and low-power communications into a small and flexible package."
For more information, visit http://www.echotx.com